Date of Birth : Jakarta/19 November 1944

QUALIFICATIONS:

1971 Dokter, Fakultas Kedokteran Indonesia, Jakarta1977 Spesialis Bedah FKUI1980 Spesialis Urologi FKUI

MEMBERSHIP:

1. Anggota Ikatan Dokter Indonesia2. Anggota Ahli Bedah Indonesia3. Anggota Ikatan Ahli Urologi Indonesia

Curriculum Vitae

Rohani Sumardi

Current Management of Lower Urinary Track Symptom (LUTS) - BPH

Rochani Sumardi

INTRODUCTION

• Lower urinary tract symptoms (LUTS) include storage and/or voiding disturbances which are very common in aging men.

INTRODUCTION

Storage VoidingFrequencyUrgencyNocturia Incontinence

Slow streamIncomplete emptyingIntermitencyHesitancyStrainingTerminal dribble

INTRODUCTION

INTRODUCTION

• Benign Prostatic Hyperplasia (BPH) is reserved for the histologic pattern the phrase describes.

• Benign Prostatic Enlargement (BPE) is used when there is gland enlargement. It is usually a presumptive diagnosis based on the size of the prostate.

INTRODUCTION

• Benign Prostatic Obstruction (BPO) is used when obstruction has been proven by pressure flow studies or is highly suspected from flow rates, and if the gland is enlarged.

• Bladder Outlet Obstruction (BOO) is the generatic term for all forms of obstruction to the bladder outlet (eg urethral stricture), including BPO.

INTRODUCTION

INTRODUCTION

INTRODUCTION

• The standard (usual) patient is a man over the age of 50 years consulting a qualified health care provider. He has lower urinary tract symptoms (LUTS) suggestive of BPO and does not have any of the specified exclusion criteria

DIAGNOSIS

HistoryAn adequate medical history should be obtained on the :

- Nature abd duration of genito-urinary tract symptoms

- Previous surgical procedures (in particular as they affect the genitourinary tract)

DIAGNOSIS

- General health issues, sexual function history- Medications currently taken by the patient,

and- The patient’s fitness for possibel surgical

procedures

DIAGNOSIS

Quantification of Symptoms : International Prostate Symptom Score (I-PSS) and Qualitu of life Assessment (QoL)

When patients present with LUTS suggesting underlying BPO, the use of a short, self-administered questionnaire in the appropirate language for the objective documentation of symptom frequency from the patient’s perspective is highly recommended.

DIAGNOSIS

a) IPSSThe I-PSS questionnaire is designed for patient self-administration. The answers are assigned

DIAGNOSIS

• points from 0 - 5. Each question allows the patient to choose one out of six answers indi cating the frequency of a particular symptom. The total score can therefore range from 0 to 35 points (asymptomatic to very symptomatic).

DIAGNOSIS

The symbol for Symptom Score is I-PSS[0-35]

Patients can be classified as follows:• 0 - 7 = mildly symptomatic• 8 - 19 = moderately symptomatic• 20 - 35 = severely symptomatic

DIAGNOSIS

• The Quality of Life Assessment (QoL) used in conjunction with the I-PSS is a single question asking the patient how he would feel about tolerating his current level of symptoms for the rest of his life. The answers to this ques tion range from delighted to terrible, or 0 to 6 points. Although this single question cannot capture the global impact of LUTS on quality of life, it may serve as a valuable starting point for a doctor-patient conversation concerning this important issue.

DIAGNOSIS The symbol for the response to the Quality

of Life Question is Qol, [0-6]

At a minimum, clinicians are encouraged to ask the single global question in the I-PSS to begin engaging their patients in a discussion about the impact of their symptoms on their lives. Clinicians may want to consider using other question sets in their practices to assess in more detail issues of continence, sexual function, and impact of symptoms on health (outlined in the report of Committee 6).

DIAGNOSIS

Physical Examination and Digital Rectal Examination (DRE)

A focused physical examination should be per formed to assess:• the suprapubic area to rule out bladder disten sion,• overall motor and sensory function.• A digital rectal examination (DRE) should be performed

to evaluate the anal sphincter tone and prostate gland with regard to approximate size, consistency, shape, and abnormalities sug gestive for prostate cancer.

DIAGNOSIS

Urinalysis• The urine should be analysed using a dipstick

test, with or without examination of the urina ry sediment after centrifugation, to determine if the patient has : haematuria, proteinuria, pyuria, or other pathological findings (e.g. glucose)

DIAGNOSIS

Serum Prostate Specific Antigen (PSA)

• Althought BPH does not lead to prostate cancer, le BPH age group are also at risk for cancer. Measurement of the serum addition to DRE clearly increases the rate of prostate cancer over DRE alone. Serum PSA measurement is recommended in the initial evaluation of patients with an anticipated life expectancy of over 10 years in whom the diagnosis of prostate cancer once established would change the treatment plan.

DIAGNOSIS

Flow Rate Recording• Urinary flow rate measurement is

recommended in the initial diagnostic assessment and during or after treatment, to determine response. Because of the non-invasive nature of the test and its clinical value, it should be performed prior to embarking on any active therapy.

DIAGNOSIS

DIAGNOSIS

• Maximum urinary flow rate (Qmax) is the best single measure; but a low Qmax does not distinguish between obstruction and decreased bladder contractility.

DIAGNOSIS

• Because of the great intra individual variability and the volume dependency of the Qmax, at least two flow rates, both with a volume ideally of > 150 ml voided urine, should be obtained. If such a voiding volume cannot he obtained by the patient despite repeated recordings, the Qmax results at available voiding volumes should be considered

DIAGNOSIS

The Qmax should be read manually as many automatic flow rate recording devices tend to overestimate Qmax due to tchnical artifacts

DIAGNOSIS

DIAGNOSIS

DIAGNOSIS

Residual Urine• The determination of post-void residual urine is

recommended in the initial diagnostic assess ment of the patient and during subsequent monitoring as a safety parameter.

• The determination is best performed by non invasive transabdominal ultrasonography. Because of the marked intra-individual varia bility of residual urine volume, the test should be repeated to improve precision, if the first residual urine volume is significant and sug gests a change in the treatment plan.

DIAGNOSIS

DIAGNOSIS

DIAGNOSIS

DIAGNOSIS

Diagnostic Tests

OPTIONAL TESTS1. Pressure-Flow Studies2. Imaging of the Prostate by Transabdominal or

Transrectal Ultrasound (TRUS)3. Imaging of the Upper Urinary Tract by

Ultrasonography or IntravenousUrography (IVU)

4. Endoscopy of the Lower Urinary Tract

INDICATION FOR SURGICAL TREATMENT

1. urinary retention (inability to urinate after at least one attempt at catheter removal)

2. recurrent gross haematuria due to BPE3. renal failure due to BPO4. bladder stones due to BPO5. recurrent urinary tract infections due to BPO, or6. large bladder diverticula,

TREATMENT

Treatment options

Watchful waiting

MedicationAlpha Blocker: tamsulosin, terazosin, alfuzosin,doxazosin5 ARI: finasteride, dutasteride min 6 mo treatment

Surgical approaches– Minimal invasive (TURP, TUIP, Laser, TUMT, TUNA)– Invasive “open” procedures : Retropubic, Transvesical

Treatment Options for BPH - Drug therapy

Class of Drug Generic Name Brand name

Alpha Blocker drug

Alfuzosin Xatral

Terazosin Hytrin

Doxazosin Cardura

Prazosin Minipress

Tamsulosin HarnalAnti androgen drug ( 5-ARI)

Finasteride Proscar

Dutasterid Avodart

Phytofarmaka Serenoa repens

Pygeum africanum

Alpha Blockers

P< 0.001

Narayan.P, et al. vol 5. The J of App Res. No.2, 2005

Reduction in BPH symptom severity was significantly greaterafter 4 weeks of treatment with tamsulosin than with terazosin

Reduction in BPH symptom severity was significantly greater after 6 weeks of treatment with tamsulosin than with doxazosin

Djoko Rahardjo, Doddy M Soebadi, Suwandi Sugandi, Ponco Birowo, Wahjoedjati, Irfan Wahyudi, International Journal of Urology (2006) 13,

1405–1409

5α-Reductase InhibitorsAdvantages Disadvantages

• Reduce prostate sizeby 20–30%

• Improve I-PSS by ~15%• Moderately improve urinary flow rates • Reduce risk of developing urinary

retention• Reduce requirement for surgery• Long-term efficacy

• Not recommended for patients with prostate size <40ml

• Side effects of reduced sexual function affect up to 12% of patients

• Reduce serum levels of PSA, which may mask detection of prostate cancer

• Take 6 months to achieve maximum efficacy

• No effect on smooth muscle component of BPH

de la Rosette J, et al, 2002. EAU guidelines on benign prostatic hyperplasia.

5α-Reductase Inhibitors

5α-Reductase Inhibitors

CONCLUSION

1. Prevalance LUTS-BPH increas with age2. Diagnostic test include - highly recommended test : history, I-PSS, QoL, DRE and

Urinalysis- recommended test : renal function test, PSA, Flow Rate

and Residual Urine3. Treatment option :- Watchful waiting - Medication : alpha blockers, 5 alpha reductation inhibitor- Surgical treatment

THANK YOU